


CLAIMS

1. The use of a compound of general formula (I)



wherein R is an aryl group selected from phenyl or benzyl, which is optionally substituted with a C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, hydroxyl, amino, nitro, amido, nitrile or a carboxyl group;


R¹ is C₁₋₆ alkyl or hydrogen;

R² is C₁₋₆ alkoxy, hydrogen, hydroxyl, or halogen; and



R³ is C₁₋₆ alkoxy, hydrogen, hydroxyl, or halogen,


for the manufacture of a medicament for the treatment of dyskinesia.

2. The use according to claim 1, wherein R is selected from the following groups:



3. The use according to claim 1 or 2, wherein when R¹ is an alkyl group it is C₂ alkyl (ethyl).
4. The use according to claim 1, 2 or 3, wherein when R² is an alkoxy group, it is C₁ alkoxy (methoxy).
5. The use according to any one of the preceding claims, wherein when R³ is an alkoxy group, it is C₁ alkoxy (methoxy).
6. The use according to any one of the preceding claims, wherein the compound of formula I is selected from the group comprising Tofisopam, Girisopam and Nerisopam (shown below):





7. The use according to claim 6, wherein the compound of formula I is Tofisopam.
8. The use according to any preceding claim, for the treatment of dyskinesia associated with movement disorders.
9. The use according to claim 8, for the treatment of dyskinesia associated with parkinsonism.
10. The use according to claim 9 wherein the parkinsonism is idiopathic Parkinson's disease or post-encephalitic parkinsonism.
11. The use according to claim 9 wherein the parkinsonism results from head injury, the treatment of schizophrenia, drug intoxication or manganese poisoning.
12. The use according to any one of claims 1 - 7 for the treatment of dyskinesia associated with Huntington's disease, idiopathic torsion dystonia, or off-dystonia in Parkinson's disease.
13. The use according to anyone of claims 1-7 for the treatment of hyperkinetic disorder associated with Tourette's syndrome and ADHD.

14. The use according to any one of claims 1 - 7 for the treatment of dyskinesia which arises as a side-effect of a therapeutic agent.
15. The use according to claim 14 for the treatment of dyskinesia associated with agents used to treat movement disorders.
16. The use according to claim 14 or 15 wherein the agent is used to treat parkinsonism.
17. The use according to claim 16 wherein the agent is a dopamine precursor.
18. The use according to claim 16 wherein the agent is a dopamine receptor agonist.
19. The use according to claim 16 wherein the agent is L-DOPA.
20. The use according to claim 16 wherein the agent is one of Chloro-APB, apomorphine, ropinirole, pramipexole, cabergoline, bromocriptine, lisuride or pergolide.
21. The use according to claim 14 wherein the agent is used to treat schizophrenia or other psychosis.
22. The use according to claim 21 wherein the agent is a neuroleptic.
23. The use according to claim 21 wherein the agent has dopamine receptor antagonist properties.
24. The use according to claim 21 wherein the agent is haloperidol, clozapine, fluphenazine or sulpiride.
25. The use according to any preceding claim for prophylactic treatment.